Denali Therapeutics (NASDAQ:DNLI) Posts Earnings Results, Beats Expectations By $0.09 EPS

Denali Therapeutics (NASDAQ:DNLI) released its earnings results on Thursday. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.09, Briefing.com reports. The firm had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $10.00 million. During the same period last year, the business earned $1.30 earnings per share. The business’s revenue was down 99.7% on a year-over-year basis.

Denali Therapeutics Trading Down 6.3 %

DNLI stock traded down $1.46 during trading on Friday, hitting $21.87. The company had a trading volume of 1,478,454 shares, compared to its average volume of 1,029,904. Denali Therapeutics has a one year low of $14.56 and a one year high of $28.31. The business has a 50-day moving average of $21.85 and a 200-day moving average of $19.61. The stock has a market cap of $3.12 billion, a PE ratio of -22.78 and a beta of 1.40.

Insider Buying and Selling at Denali Therapeutics

In related news, Director Jennifer E. Cook sold 1,458 shares of the stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $21.73, for a total value of $31,682.34. Following the completion of the sale, the director now directly owns 20,038 shares of the company’s stock, valued at approximately $435,425.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $22.12, for a total transaction of $663,600.00. Following the completion of the sale, the director now owns 34,404 shares in the company, valued at approximately $761,016.48. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jennifer E. Cook sold 1,458 shares of Denali Therapeutics stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $21.73, for a total value of $31,682.34. Following the sale, the director now owns 20,038 shares of the company’s stock, valued at approximately $435,425.74. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,146 shares of company stock valued at $710,274. 7.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. UBS Group decreased their target price on shares of Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, April 9th. Wedbush dropped their price objective on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research note on Friday. Stifel Nicolaus lowered their target price on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a report on Wednesday, May 8th. Citigroup increased their price objective on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a report on Friday. Finally, JPMorgan Chase & Co. upped their target price on shares of Denali Therapeutics from $28.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $39.89.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.